000147339 001__ 147339
000147339 005__ 20240229112648.0
000147339 0247_ $$2doi$$a10.1016/j.isci.2019.09.032
000147339 0247_ $$2pmid$$apmid:31610370
000147339 0247_ $$2altmetric$$aaltmetric:67284633
000147339 037__ $$aDKFZ-2019-02460
000147339 041__ $$aeng
000147339 082__ $$a050
000147339 1001_ $$aTsunekawa, Taku$$b0
000147339 245__ $$aGABAB Receptor Signaling in the Mesolimbic System Suppresses Binge-like Consumption of a High-Fat Diet.
000147339 260__ $$aSt. Louis$$bElsevier$$c2019
000147339 3367_ $$2DRIVER$$aarticle
000147339 3367_ $$2DataCite$$aOutput Types/Journal article
000147339 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692363498_16345
000147339 3367_ $$2BibTeX$$aARTICLE
000147339 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147339 3367_ $$00$$2EndNote$$aJournal Article
000147339 520__ $$aBinge eating could contribute to the development of obesity, and previous studies suggest that gamma-aminobutyric acid (GABA) type B receptor (GABABR) signaling is involved in the regulation of binge eating. Here, we show that time-restricted access to a high-fat diet (HFD) induces binge-like eating behavior in wild-type mice. HFD consumption during restricted time was significantly increased in corticostriatal neuron-specific GABABR-deficient mice compared with wild-type mice. Furthermore, the GABABR agonist baclofen suppressed HFD intake during restricted time in wild-type mice but not in corticostriatal or dopaminergic neuron-specific GABABR-deficient mice. In contrast, there were no significant differences in food consumption among genotypes under ad libitum access to HFD. Thus, our data show that the mesolimbic system regulates food consumption under time-restricted but not ad libitum access to HFD and have identified a mechanism by which GABABR signaling suppresses binge-like eating of HFD.
000147339 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000147339 588__ $$aDataset connected to CrossRef, PubMed,
000147339 7001_ $$aBanno, Ryoichi$$b1
000147339 7001_ $$aYaginuma, Hiroshi$$b2
000147339 7001_ $$aTaki, Keigo$$b3
000147339 7001_ $$aMizoguchi, Akira$$b4
000147339 7001_ $$aSugiyama, Mariko$$b5
000147339 7001_ $$aOnoue, Takeshi$$b6
000147339 7001_ $$aTakagi, Hiroshi$$b7
000147339 7001_ $$0P:(DE-HGF)0$$aHagiwara, Daisuke$$b8
000147339 7001_ $$aIto, Yoshihiro$$b9
000147339 7001_ $$aIwama, Shintaro$$b10
000147339 7001_ $$aGoto, Motomitsu$$b11
000147339 7001_ $$aSuga, Hidetaka$$b12
000147339 7001_ $$aBettler, Bernhard$$b13
000147339 7001_ $$aArima, Hiroshi$$b14
000147339 773__ $$0PERI:(DE-600)2927064-9$$a10.1016/j.isci.2019.09.032$$gVol. 20, p. 337 - 347$$p337 - 347$$tiScience$$v20$$x2589-0042$$y2019
000147339 909CO $$ooai:inrepo02.dkfz.de:147339$$pVDB
000147339 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000147339 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000147339 9141_ $$y2019
000147339 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bISCIENCE : 2021$$d2022-11-16
000147339 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-16
000147339 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-16
000147339 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-06-28T09:42:31Z
000147339 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-06-28T09:42:31Z
000147339 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-06-28T09:42:31Z
000147339 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-16
000147339 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-16
000147339 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-16
000147339 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-16
000147339 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-16
000147339 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bISCIENCE : 2021$$d2022-11-16
000147339 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-16
000147339 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-16
000147339 9201_ $$0I:(DE-He78)V078-20160331$$kV078$$lAG Neuropeptide$$x0
000147339 980__ $$ajournal
000147339 980__ $$aVDB
000147339 980__ $$aI:(DE-He78)V078-20160331
000147339 980__ $$aUNRESTRICTED